TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11556579
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of albendazole 400 mg plus praziquantel 40 mg/kg daily (A3P3, n=36)
Study: 9563866
Drug: TIVA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA using propofol with alfentanil (high infusion rate)
Study: 9563866
Drug: TIVA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA using propofol with alfentanil (low infusion rate)
Study: 30634206
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (60 cases)
Study: 24710341
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of CPAP therapy
Study: 20707248
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) group: hyperbaric bupivacaine 15 mg plus 100 mcg of preservative-free morphine
Study: 20707248
Drug: Single-shot ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot ultrasound-guided femoral nerve block (FNB) group: ropivacaine 0.75% 25 ml
Study: 12807337
Drug: EPs 7630
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630 (30 drops three times daily for 7 days)
Study: 8865711
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anesthesia with 0.5% isoflurane, nitrous oxide, oxygen and intravenous fentanyl
Study: 1510899
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam administered in conscious sedation doses
Study: 6084856
Drug: Irradiation (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation (30 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Study: 6084856
Drug: Irradiation (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation (55 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Study: 6084856
Drug: Bleomycin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin and adriamycin treatment
Study: 26634942
Drug: Intravaginal 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 0.50% (6.5 mg) DHEA administered daily for 12 weeks
Study: 26634942
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 12 weeks
Study: 25283469
Drug: Composite of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite of 5 daily pain intensity ratings
Study: 25283469
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily pain intensity rating
Study: 18807079
Drug: Pulse transit
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse transit time (PTT) measurement before orthodontic treatment
Study: 18807079
Drug: Pulse transit
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse transit time (PTT) measurement after orthodontic treatment
Study: 18807079
Drug: Pre-treatment status
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment status
Study: 12789992
Drug: 18% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% carbamide peroxide gel (Colgate Simply White Clear Whitening Gel) applied twice daily after brushing with a nonwhitening dentifrice
Study: 12789992
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available whitening dentifrice used twice daily for brushing
Study: 9583844
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ascorbic acid
Study: 9583844
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ascorbic acid
Study: 7633987
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment (control)
Study: 29136625
Drug: Fluoridated salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated salt (250 mg F-/kg salt) used in meals for the intervention group
Study: 23233657
Drug: Thalidomide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (50 mg daily for 2 years)
Study: 17872899
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy in ER-negative/PrPc-positive disease
Study: 17872899
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy in ER-negative/PrPc-negative tumors
Study: 15480326
Drug: Coseasonal sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coseasonal sublingual immunotherapy (SLIT) for 3 years
Study: 15480326
Drug: Standard symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard symptomatic therapy (control)
Study: 9764616
Drug: Mifepristone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (400 mg orally)
Study: 15932638
Drug: Glucose-insulin-potassium infusion
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium infusion (GIK)
Study: 2837991
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day b.i.d. combined with FT‐207 600 mg/day t.i.d.
Study: 28961815
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic prescription monitoring and feedback based on health insurance claims data
Study: 22903141
Drug: Steep Ramp
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steep Ramp Test (SRT); performed twice within 2 weeks; main outcome: Peak Work Rate (WRpeak)
Study: 21483491
Drug: Interruption before
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interruption before re‐treatment
Study: 21483491
Drug: Re‐treatment options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re‐treatment options
Study: 16765793
Drug: cyclosporine 0.05%
Normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine 0.05% ophthalmic emulsion
Study: 11087764
Drug: IVIg (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (0.4 g/kg/d for 5 consecutive days)
Study: 1609951
Drug: Diazepam 0.5
Normalized name: diazepam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.5 mg/kg
Study: 4082242
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg every 6 h (Phase B)
Study: 4082242
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg every 6 h (Phase C)
Study: 4082242
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg) (Phase A)
Study: 30261748
Drug: VacuMed® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VacuMed® treatment thrice weekly for 6 weeks
Study: 25732417
Drug: UDCA monotherapy
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA monotherapy
Study: 20598621
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of symptomatic therapy
Study: 18036365
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day rosuvastatin
Study: 8623801
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized dehydroepiandrosterone 300 mg
Study: 8623801
Drug: Oral crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral crystalline dehydroepiandrosterone 300 mg
Study: 8623801
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized dehydroepiandrosterone 150 mg
Study: 8623801
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized dehydroepiandrosterone 150 mg
Study: 1952858
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil at 250 mg
Study: 1952858
Drug: Cefaclor at
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor at 250 mg
Study: 1952858
Drug: Cefaclor at
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor at 375 mg
Study: 1952858
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily
Study: 7039204
Drug: Cimetidine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.2 grams daily for 35 days)
Study: 31433518
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) 5 mg infusion
Study: 31433518
Drug: Denosumab (Dmab)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (Dmab) 60 mg injections (2 additional injections)
Study: 29970736
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (Group A) 1 mg/kg for two weeks
Study: 29970736
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (Group B) 30 mg/kg for three days followed by oral prednisolone 1 mg/kg for two weeks
Study: 22774791
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Cognitive Therapy + Antidepressant medication)
Study: 20716770
Drug: Zosuquidar (550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zosuquidar (550 mg)
Study: 12422079
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (ampicillin/sulbactam, 25 mg/kg/daily)
Study: 12422079
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment combined with intranasal budesonide (200 mg/daily)
Study: 11938741
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg administered intravenously)
Study: 11938741
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no diazepam administered)
Study: 2046138
Drug: CV-4151 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV-4151 (selective inhibitor of thromboxane A2 synthetase), administered greater than or equal to 2 days before angioplasty and continued until follow-up (3-6 months after angioplasty)
Study: 28650194
Drug: Internet-delivered parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered parent-child interaction therapy (I-PCIT)
Study: 28650194
Drug: clinic-based parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinic-based parent-child interaction therapy (PCIT)
Study: 26076571
Drug: Chronic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic glucose metabolism disorders (A)
Study: 19549020
Drug: 1,800 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg/d EPA-DHA (n=96)
Study: 19549020
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d EPA-DHA (n=100)
Study: 19549020
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (n=106)
Study: 10799351
Drug: Octreotide 200
Normalized name: octreotide 200 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 200 microgram s.c. 3 times daily, starting the night before endoscopic procedures
Study: 10799351
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily, starting the night before endoscopic procedures
Study: 1381640
Drug: Teicoplanin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin, 400 mg i.v., given as a single dose
Study: 16122283
Drug: Crushed moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with water (regimen B)
Study: 16122283
Drug: Crushed moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with enteral feeding (regimen C)
Study: 16122283
Drug: Intact moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact moxifloxacin 400 mg tablet (regimen A, reference treatment)
Study: 10402079
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 30 mg ketoprofen plaster (n = 40)
Study: 10402079
Drug: Multiple applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple applications of 30 mg ketoprofen plaster for 5 days (n = 30)
Study: 10402079
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 50 mg ketoprofen (n = 30)
Study: 7594331
Drug: Lansoprazole injection
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole injection 30 mg once daily
Study: 7594331
Drug: Lansoprazole injection
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole injection 30 mg twice daily
Study: 7594331
Drug: Lansoprazole injection
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole injection 15 mg twice daily
Study: 7594331
Drug: Histamine H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2-receptor antagonist 20 mg twice daily
Study: 22182865
Drug: Continuous intercostal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intercostal nerve block (CINB) with 0.2% ropivacaine infusion
Study: 14759615
Drug: Cyclofem (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofem (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Study: 14759615
Drug: NET-EN (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: NET-EN (norethisterone enanthate 200 mg)
Study: 11772793
Drug: Preoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative thoracic epidural analgesia (TEA) with bupivacaine and morphine solution, postoperative epidural PCA
Study: 11772793
Drug: Postoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative thoracic epidural analgesia (TEA) with bolus dose
Study: 11772793
Drug: IV patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV patient‐controlled analgesia (IV‐PCA) with morphine
Study: 9690692
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day (group 1)
Study: 9690692
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day (group 2)
Study: 2668978
Drug: Minaprine 400
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 400 mg daily
Study: 403395
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with radiotherapy (5000 rads) and ICRF 159 (250 mg p.d.)
Study: 403395
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with radiotherapy and ICRF 159
Study: 27629581
Drug: Risk Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk Reduction Therapy for Adolescents (RRTA)
Study: 27136912
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg under high-fat breakfast conditions
Study: 27136912
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg under low-fat breakfast conditions
Study: 27136912
Drug: Fedratinib 100
Normalized name: fedratinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedratinib 100 mg under high-fat breakfast conditions
Study: 27136912
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg under fasted conditions
Study: 23873570
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with 125 µg OMP alone
Study: 23873570
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with OMP+NP
Study: 23873570
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with OMP only
Study: 23873570
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with or without NP
Study: 23873570
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination with 125 µg OMP alone and OMP+NP
Study: 19371311
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion at 30 microg min(‐1)
Study: 19371311
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion at 100 microg min(‐1)
Study: 19371311
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion at 50 microg min(‐1)
Study: 19371311
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with antihistamines pretreatment
Study: 19371311
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with nitric oxide clamp
Study: 10696747
Drug: Subconjunctival mydricaine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival mydricaine and topical diclofenac 0.1%
Study: 3492759
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim twice a day
Study: 3492759
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg trimethoprim plus 800 mg sulphamethoxazole twice a day
Study: 22732846
Drug: Sublingual ketorolac
Normalized name: ketorolac Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ketorolac (10 mg 4 times daily)
Study: 22732846
Drug: Sublingual piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual piroxicam (20 mg once daily)
Study: 9523857
Drug: Drinking water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking water with less than 1.57 micromol/l (<0.1 mg/l)
Study: 9523857
Drug: Drinking water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking water with 31.48 micromol/l (2 mg/l) of copper
Study: 2568660
Drug: Triprolidine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (7.5 mg)
Study: 798330
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone therapy at the time of kidney transplantation
Study: 31448392
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (triamcinolone in 2% xylocaine)
Study: 20591206
Drug: Very-long-chain inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very-long-chain inulin (VLCI) 10 g/d
Study: 20591206
Drug: Maltodextrin (placebo)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (placebo) 10 g/d
Study: 8578060
Drug: Gabapentin as
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin as add-on therapy; different dosages not specified.
Study: 6123647
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (assumed benefit for rapid growth stratum)
Study: 29229000
Drug: Self-administered, computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, computerized SBIRT intervention
Study: 29229000
Drug: Clinician-administered SBIRT
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-administered SBIRT intervention
Study: 17570119
Drug: Vicriviroc 5
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 5 mg
Study: 17570119
Drug: Vicriviroc 10
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 10 mg
Study: 17570119
Drug: Vicriviroc 15
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 15 mg
Study: 10546931
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg of intravitreal TPA in buffered salt solution (BSS) 15 minutes before vitrectomy
Study: 7477217
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of oral lamivudine daily for 12 weeks
Study: 7477217
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral lamivudine daily for 12 weeks
Study: 7477217
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of oral lamivudine daily for 12 weeks
Study: 7477217
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg or 300 mg of oral lamivudine daily for 12 weeks
Study: 2124651
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acid (BCAA) administration postoperatively in gastrectomized rats and in humans after subtotal or total gastrectomy.
Study: 2124651
Drug: Conventional total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional total parenteral nutrition with a Calorie/N ratio of about 150.
Study: 7047460
Drug: Aspirin (acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (acetylsalicylic acid)